CHRIS AMOS to Drug Resistance, Neoplasm
This is a "connection" page, showing publications CHRIS AMOS has written about Drug Resistance, Neoplasm.
Connection Strength
0.602
-
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. Int J Cancer. 2020 11 01; 147(9):2621-2633.
Score: 0.464
-
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016 May; 209(5):195-8.
Score: 0.087
-
PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Jan 15; 23(2):399-406.
Score: 0.022
-
Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. Mol Cancer. 2015 Feb 03; 14:29.
Score: 0.020
-
An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2002 Jul 17; 94(14):1091-9.
Score: 0.008